The IRA could have the effect of reducing the prices we can charge and reimbursement we receive for future products or product candidates, if approved, thereby reducing our profitability, and could have a material adverse effect on our financial condition, results of operations, and growth prospects. The full impact of the IRA on the pharmaceutical industry in general remains uncertain.
